Trovagene Investor Relations http://trovagene.investorroom.com/ Trovagene Investor Relations Trovagene to Provide Update on Onvansertib Clinical Development Program on Wednesday, October 24, 2018 http://trovagene.investorroom.com/2018-10-18-Trovagene-to-Provide-Update-on-Onvansertib-Clinical-Development-Program-on-Wednesday-October-24-2018 -Webcast and Conference Call for Investors and Analysts on Wednesday, October 24th at 8:30 am EDT Thu, 18 Oct 2018 05:30:00 -0700 http://trovagene.investorroom.com/2018-10-18-Trovagene-to-Provide-Update-on-Onvansertib-Clinical-Development-Program-on-Wednesday-October-24-2018 Trovagene Announces Exclusive License Agreement with MIT for Combination Therapy of Anti-Androgens and Polo-like Kinase Inhibitors in Prostate Cancer http://trovagene.investorroom.com/2018-10-03-Trovagene-Announces-Exclusive-License-Agreement-with-MIT-for-Combination-Therapy-of-Anti-Androgens-and-Polo-like-Kinase-Inhibitors-in-Prostate-Cancer Patent agreement covers rights to develop combination therapies and identified predictive clinical biomarker across cancer types, expanding indications for Onvansertib Wed, 03 Oct 2018 05:30:00 -0700 http://trovagene.investorroom.com/2018-10-03-Trovagene-Announces-Exclusive-License-Agreement-with-MIT-for-Combination-Therapy-of-Anti-Androgens-and-Polo-like-Kinase-Inhibitors-in-Prostate-Cancer Trovagene Announces Completion of Dosing Cohort of Patients Treated with Onvansertib in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial http://trovagene.investorroom.com/2018-09-27-Trovagene-Announces-Completion-of-Dosing-Cohort-of-Patients-Treated-with-Onvansertib-in-Combination-with-Decitabine-in-Ongoing-Phase-1b-2-AML-Trial Safety Review Committee (SRC) recommends proceeding to the next dose level cohort of Onvansertib in combination with decitabine in dose-escalation phase of trial Thu, 27 Sep 2018 05:30:00 -0700 http://trovagene.investorroom.com/2018-09-27-Trovagene-Announces-Completion-of-Dosing-Cohort-of-Patients-Treated-with-Onvansertib-in-Combination-with-Decitabine-in-Ongoing-Phase-1b-2-AML-Trial Trovagene Announces Participation at The MicroCap Conference on October 1st and 2nd at the Essex House in New York City http://trovagene.investorroom.com/2018-09-18-Trovagene-Announces-Participation-at-The-MicroCap-Conference-on-October-1st-and-2nd-at-the-Essex-House-in-New-York-City Company overview, update on Onvansertib clinical development program and anticipated near-term value-creation milestones Tue, 18 Sep 2018 05:30:00 -0700 http://trovagene.investorroom.com/2018-09-18-Trovagene-Announces-Participation-at-The-MicroCap-Conference-on-October-1st-and-2nd-at-the-Essex-House-in-New-York-City Trovagene Announces Predictive Clinical Biomarker Approach to Identify Acute Myeloid Leukemia (AML) Patients Most Likely to Respond to Onvansertib http://trovagene.investorroom.com/2018-09-05-Trovagene-Announces-Predictive-Clinical-Biomarker-Approach-to-Identify-Acute-Myeloid-Leukemia-AML-Patients-Most-Likely-to-Respond-to-Onvansertib Target engagement and inhibition of PLK1 by Onvansertib predictive of treatment response Wed, 05 Sep 2018 05:00:00 -0700 http://trovagene.investorroom.com/2018-09-05-Trovagene-Announces-Predictive-Clinical-Biomarker-Approach-to-Identify-Acute-Myeloid-Leukemia-AML-Patients-Most-Likely-to-Respond-to-Onvansertib